KR20220004105A - 통합 스트레스 반응 경로의 조절제 - Google Patents

통합 스트레스 반응 경로의 조절제 Download PDF

Info

Publication number
KR20220004105A
KR20220004105A KR1020217037824A KR20217037824A KR20220004105A KR 20220004105 A KR20220004105 A KR 20220004105A KR 1020217037824 A KR1020217037824 A KR 1020217037824A KR 20217037824 A KR20217037824 A KR 20217037824A KR 20220004105 A KR20220004105 A KR 20220004105A
Authority
KR
South Korea
Prior art keywords
chloro
acetamide
piperidin
fluorophenoxy
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217037824A
Other languages
English (en)
Korean (ko)
Inventor
홀리 애튼
크리스토퍼 존 브라운
제임스 린제이 캐르
세르게 컨버스-레이그니어
마이클 코르
마리샤 플로워
크리스토퍼 프랜시스 팔머
이레나 돌리 레볼레
모하메드 사바흐
스콧 새들러
조나단 샤인
대릴 사이먼 월터
Original Assignee
에보텍 인터내셔널 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에보텍 인터내셔널 게엠베하 filed Critical 에보텍 인터내셔널 게엠베하
Publication of KR20220004105A publication Critical patent/KR20220004105A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of El Displays (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Semiconductor Integrated Circuits (AREA)
KR1020217037824A 2019-04-23 2020-04-22 통합 스트레스 반응 경로의 조절제 Pending KR20220004105A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170504.5 2019-04-23
EP19170504 2019-04-23
EP19216875.5 2019-12-17
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
KR20220004105A true KR20220004105A (ko) 2022-01-11

Family

ID=70289816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037824A Pending KR20220004105A (ko) 2019-04-23 2020-04-22 통합 스트레스 반응 경로의 조절제

Country Status (15)

Country Link
US (2) US12258338B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959198A1 (cg-RX-API-DMAC7.html)
JP (2) JP7590343B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004105A (cg-RX-API-DMAC7.html)
CN (1) CN113993850B (cg-RX-API-DMAC7.html)
AU (2) AU2020261234B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020402A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002772A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014292A2 (cg-RX-API-DMAC7.html)
IL (1) IL287379B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021012903A (cg-RX-API-DMAC7.html)
PE (1) PE20220961A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111119PA (cg-RX-API-DMAC7.html)
WO (1) WO2020216766A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108151B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) * 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
MX2021012904A (es) * 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
MX2023004677A (es) * 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
WO2022212902A1 (en) * 2021-04-02 2022-10-06 Altos Labs, Inc. Modulators of integrated stress response pathway
AU2023384649A1 (en) 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
CN116854623B (zh) * 2023-07-11 2025-08-05 齐鲁安替制药有限公司 一种阿维巴坦中间体的制备方法
CN121986087A (zh) 2023-10-13 2026-05-05 国立研究开发法人国立精神·神经医疗研究中心 神经保护剂
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639761B1 (en) 1999-12-02 2003-10-28 Seagate Technology Llc Micro-actuator damping and humidity protection
AU2001233044A1 (en) * 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
US7915433B2 (en) 2004-04-16 2011-03-29 Wayne State University Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
WO2017046739A1 (en) 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
RU2018145734A (ru) * 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
DE102017213834A1 (de) * 2017-08-08 2019-02-14 Robert Bosch Gmbh Sende-/Empfangseinrichtung für ein Bussystem und Verfahren zur Reduzierung einer Schwingneigung beim Übergang zwischen unterschiedlichen Bitzuständen
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Also Published As

Publication number Publication date
JP2022530049A (ja) 2022-06-27
PE20220961A1 (es) 2022-06-10
AU2026203062A1 (en) 2026-05-07
WO2020216766A1 (en) 2020-10-29
SG11202111119PA (en) 2021-11-29
JP2025024086A (ja) 2025-02-19
IL287379B1 (en) 2025-07-01
US20220227747A1 (en) 2022-07-21
IL287379B2 (en) 2025-11-01
US12258338B2 (en) 2025-03-25
JP7878648B2 (ja) 2026-06-23
CA3137213A1 (en) 2020-10-29
BR112021020402A2 (pt) 2021-12-07
US20250188071A1 (en) 2025-06-12
CO2021014292A2 (es) 2022-04-29
CN113993850A (zh) 2022-01-28
IL287379A (en) 2021-12-01
AU2020261234A1 (en) 2021-11-11
MX2024015479A (es) 2025-02-10
ZA202108151B (en) 2026-04-29
EP3959198A1 (en) 2022-03-02
MX2021012903A (es) 2022-01-18
AU2020261234B2 (en) 2026-02-05
CL2021002772A1 (es) 2022-07-29
JP7590343B2 (ja) 2024-11-26
CN113993850B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
JP7590343B2 (ja) 統合ストレス応答経路のモジュレーター
US11639353B2 (en) Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
ES2866152T3 (es) Derivados de tirosina amida como inhibidores de la Rho-quinasa
JP7699595B2 (ja) 統合的ストレス応答経路の調節因子
MX2015006038A (es) Moduladores de pirrolidina del receptor acoplado a la proteina g (gpr40).
JP2022533147A (ja) 芳香族アミン類のar及びbetを標的とするタンパク質分解キメラ化合物及び使用
KR20220151635A (ko) 통합 스트레스 반응 경로의 조절제
AU2021367147A1 (en) Modulators of the integrated stress response pathway
AU2021363616A1 (en) Modulators of the integrated stress response pathway
EA046988B1 (ru) Модуляторы пути интегрированной реакции на стресс
HK40068295A (en) Modulators of the integrated stress response pathway
EA048846B1 (ru) Модуляторы пути интегрированного ответа на стресс
EA051407B1 (ru) Модуляторы пути интегрированного ответа на стресс
EA051483B1 (ru) Модуляторы пути интегрированного ответа на стресс
EA048763B1 (ru) Модулятор пути интегрированного ответа на стресс и его применение
HK40068295B (en) Modulators of the integrated stress response pathway

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000